Chris Boshoff
Chris Boshoff is the Chief Scientific Officer at Pfizer, where he plays a pivotal role in the development of innovative pharmaceutical solutions. Recently, he was in the news for announcing the halt of the development of Danuglipron, an experimental weight-loss medication, following reports of liver damage in a patient during trials, despite the patient showing no symptoms or side effects.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Argentina | 1 | 7.00 | 0.07% | +0% | 45,195,774 | 33,330 | $450,000 | 332$ |
| Totals | 1 | 45,195,774 | 33,330 | $450,000 | 332$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Argentina:
Chris Boshoff is the Chief Scientific Officer and President of Research and Development at Pfizer.
7
Hungary:
Chris Boshoff is the scientific director of Pfizer who commented on the halt of the Danuglipron development.
5